Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II Open Label Study to Evaluate the Effect of GBT440 on Hypoxemia in Subjects With Idiopathic Pulmonary Fibrosis (IPF) Who Are Using Supplemental Oxygen at Rest (ZEPHYR)

NCT02989168 is registered in ClinicalTrials.gov with Global Blood Therapeutics as lead sponsor.

NCT NCT02989168
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02989168 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II Open Label Study to Evaluate the Effect of GBT440 on Hypoxemia in Subjects With Idiopathic Pulmonary Fibrosis (IPF) Who Are Using Supplemental Oxygen at Rest (ZEPHYR)
Lead sponsor
Global Blood Therapeutics
Phase
Phase 2
Overall status
Terminated
Start date
November 30, 2016
Completion date
October 23, 2017
Enrollment
14 (actual)
Sites
9

Conditions

As the registry lists them; a condition with its own page is linked.

hypoxemia, idiopathic pulmonary fibrosis